[Adalimumab for Crohn's disease. Monotherapy or combination therapy? -Discussion with results from DIAMOND study]

Nihon Shokakibyo Gakkai Zasshi. 2019;116(3):193-199. doi: 10.11405/nisshoshi.116.193.

[Article in Japanese]

Authors

Tadakazu Hisamatsu¹, Daisuke Saito¹, Ryo Ozaki¹

Affiliation

¹ The Third Department of Internal Medicine, Kyorin University School of Medicine.

PMID: 30853671
DOI: 10.11405/nisshoshi.116.193

No abstract available

MeSH terms

Adalimumab / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Crohn Disease / drug therapy*
Drug Therapy, Combination
Humans
Immunosuppressive Agents
Infliximab
Treatment Outcome

Substances

Anti-Inflammatory Agents
Immunosuppressive Agents
Infliximab
Adalimumab